Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $158.5M
- Enterprise value
- $158.5M
- P/E (trailing)
- 149.6×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $80.00
- 52-wk low
- $7.60
- Beta
- —
- Shares out
- 3.2M
5-year trend
What this company does
Aimei Health Technology is a Cayman Islands blank-check SPAC formed in 2023 to acquire a small-cap business in biopharma, medical devices, diagnostics, or healthcare services. It has no operations or revenue; it holds roughly $69.7 million in trust from its December 2023 IPO, earning interest until a deal closes or funds are returned. The company has signed a definitive merger agreement with United Hydrogen Group and extended its deadline to complete a combination to up to 36 months post-IPO.
Generated from AFJKU's filing dated 2026-05-04
Key risks
- Deadline risk: SPAC must close United Hydrogen deal by December 2026 (36-month extended limit) or liquidate Trust and dissolve.
- Single-target dependency: Entire thesis hinges on June 2024 United Hydrogen merger closing, pending shareholder votes, F-4 effectiveness, and CSRC approvals.
- Redemption/dilution risk: Closing requires $5,000,001 net tangible assets post-redemption; heavy redemptions could break the deal or leave minimal float.
Generated from AFJKU's filing dated 2026-05-04
Profitability
Return on equity
-71.8%
96.2%Return on assets
8.8%
153.2%Leverage
Debt / equity
-9.20×
98.3%Debt / assets
112.2%
12.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | — | — | $98.1K | -77.9% | — |
Q3 2025 2025-09-30 | — | — | $352.0K | -52.7% | — |
Q2 2025 2025-06-30 | — | — | $425.0K | -30.2% | — |
Q1 2025 2025-03-31 | — | — | $184.7K | -75.6% | — |
Q4 2024 2024-12-31 | — | — | $444.1K | — | — |
Q3 2024 2024-09-30 | — | — | $743.5K | +20650.3% | — |
Q2 2024 2024-06-30 | — | — | $609.1K | — | — |
Q1 2024 2024-03-31 | — | — | $755.5K | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Blank Checks · SIC 6770
Your notes
Keep private notes on AFJKU — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for AFJKU in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns AFJKU
Institutional value
$25.6K
Total shares held
2.3K
Distinct holders
2
+0 vs prior
As of
2025-09-30
Prior: 2025-06-30
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Clear Street Group Inc. | 2.3K | $25.6K | — | New |
| 2 | UBS Group AG | 7 | $78 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
With the United Hydrogen deal pending since June 2024, what specific closing conditions remain unmet and what's your realistic completion date?
- 2
Why pivot from biopharma/medtech mandate to hydrogen via United Hydrogen, and what diligence justifies that strategic departure for shareholders?
- 3
What's the current Trust Account balance after extensions, and what monthly sponsor contributions fund the 24 one-month extensions through December 2026?
Refreshed when AFJKU files a new report · last from 2026-05-04